Industrial toxicants and Parkinson's disease

NeuroToxicology

Volumn 33, Issue 2, 2012, Pages 178-188

  Caudle, W Michael ^a   Guillot, Thomas S ^a   Lazo, Carlos R ^a   Miller, Gary W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Industrial toxicants; Parkinson's disease; Parkinsonism

Indexed keywords

COPPER; INDUSTRIAL CHEMICAL; IRON; LEAD; MANGANESE; MERCURY; METAL; METHANOL; NANOPARTICLE; ORGANOHALOGEN DERIVATIVE; POLYBROMINATED DIPHENYL ETHER; POLYCHLORINATED BIPHENYL; SOLVENT; TRICHLOROETHYLENE;

DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; HUMAN; IRON OVERLOAD; LEAD POISONING; LIPID PEROXIDATION; LIPOPHILICITY; LONG TERM EXPOSURE; MERCURIALISM; METAL METABOLISM; METHANOL POISONING; MOLECULAR DYNAMICS; NEUROPATHOLOGY; NEUROTOXICITY; NEUROTOXICOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION;

ENVIRONMENTAL EXPOSURE; HAZARDOUS SUBSTANCES; HUMANS; PARKINSON DISEASE; RISK FACTORS;

EID: 84856980268     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2012.01.010     Document Type: Review

References (165)

1. Alaee M., Sergeant D.B., Ikonomou M.G., Luross J.M. A gas chromatography/high-resolution mass spectrometry (GC/HRMS) method for determination of polybrominated diphenyl ethers in fish. Chemosphere 2001, 44:1489-1495.
2. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989, 12:366-375.
3. Ascherio A., Chen H., Weisskopf M.G., O'Reilly E., McCullough M.L., Calle E.E., et al. Pesticide exposure and risk for Parkinson's disease. Ann Neurol 2006, 60:197-203.
4. Aschner M., Erikson K.M., Dorman D.C. Manganese dosimetry: species differences and implications for neurotoxicity. Crit Rev Toxicol 2005, 35:1-32.
5. Barbeau A., Friesen H. Treatment of Wilson's disease with l-dopa after failure with penicillamine. Lancet 1970, 1:1180-1181.
6. Barthel H., Hermann W., Kluge R., Hesse S., Collingridge D.R., Wagner A., et al. Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease. AJNR Am J Neuroradiol 2003, 24:234-238.
7. Bemis J.C., Seegal R.F. PCB-induced inhibition of the vesicular monoamine transporter predicts reductions in synaptosomal dopamine content. Toxicol Sci 2004, 80:288-295.
8. Borisova T., Krisanova N., Sivko R., Kasatkina L., Borysov A., Griffin S., et al. Presynaptic malfunction: the neurotoxic effects of cadmium and lead on the proton gradient of synaptic vesicles and glutamate transport. Neurochem Int 2011, 59:272-279.
9. Bourdineaud J.P., Fujimura M., Laclau M., Sawada M., Yasutake A. Deleterious effects in mice of fish-associated methylmercury contained in a diet mimicking the Western populations' average fish consumption. Environ Int 2011, 37:303-313.
10. Braak H., Braak E., Yilmazer D., Schultz C., de Vos R.A., Jansen E.N. Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl 1995, 46:15-31.
11. Brenneman K.A., Wong B.A., Buccellato M.A., Costa E.R., Gross E.A., Dorman D.C. Direct olfactory transport of inhaled manganese ((54)MnCl(2)) to the rat brain: toxicokinetic investigations in a unilateral nasal occlusion model. Toxicol Appl Pharmacol 2000, 169:238-248.
12. Bringmann G., Friedrich H., Feineis D. Trichloroharmanes as potential endogenously formed inducers of Morbus Parkinson: synthesis, analytics, and first in vivo-investigations. J Neural Transm Suppl 1992, 38:15-26.
13. Brouillet E.P., Shinobu L., McGarvey U., Hochberg F., Beal M.F. Manganese injection into the rat striatum produces excitotoxic lesions by impairing energy metabolism. Exp Neurol 1993, 120:89-94.
14. Burgess W. Welding. Recognition of health hazards in industry: a review of materials and processes 1995, 167-204. John Wiley & Sons, New York. W. Burgess (Ed.).
15. Carcaba V., Garcia Amorin Z., Rodriguez Junquera R., Velasco L. Parkinsonism and putaminal lesion from methanol intoxication. An Med Interna 2002, 19:438-439.
16. Caudle W.M., Colebrooke R.E., Emson P.C., Miller G.W. Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci 2008, 31:303-308.
17. Caudle W.M., Richardson J.R., Delea K.C., Guillot T.S., Wang M., Pennell K.D., et al. Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity. Toxicol Sci 2006, 92:490-499.
18. Caudle W.M., Richardson J.R., Wang M.Z., Taylor T.N., Guillot T.S., McCormack A.L., et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 2007, 27:8138-8148.
19. Chen M.K., Lee J.S., McGlothan J.L., Furukawa E., Adams R.J., Alexander M., et al. Acute manganese administration alters dopamine transporter levels in the non-human primate striatum. Neurotoxicology 2006, 27:229-236.
20. Cohen G. Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 1984, 5:77-82.
21. Cole W.J., Mitchell R.G., Salamonsen R.F. Isolation, characterization and quantitation of chloral hydrate as a transient metabolite of trichloroethylene in man using electron capture gas chromatography and mass fragmentography. J Pharm Pharmacol 1975, 27:167-171.
22. Coon S., Stark A., Peterson E., Gloi A., Kortsha G., Pounds J., et al. Whole-body lifetime occupational lead exposure and risk of Parkinson's disease. Environ Health Perspect 2006, 114:1872-1876.
23. Corrigan F.M., Murray L., Wyatt C.L., Shore R.F. Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease. Exp Neurol 1998, 150:339-342.
24. Corrigan F.M., Wienburg C.L., Shore R.F., Daniel S.E., Mann D. Organochlorine insecticides in substantia nigra in Parkinson's disease. J Toxicol Environ Health A 2000, 59:229-234.
25. Crossman A.R. Neural mechanisms in disorders of movement. Comp Biochem Physiol A 1989, 93:141-149.
26. Cui M., Aras R., Christian W.V., Rappold P.M., Hatwar M., Panza J., et al. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci USA 2009, 106:8043-8048.
27. Darnerud P.O., Eriksen G.S., Johannesson T., Larsen P.B., Viluksela M. Polybrominated diphenyl ethers: occurrence, dietary exposure, and toxicology. Environ Health Perspect 2001, 109(Suppl. 1):49-68.
28. de Wit C.A. An overview of brominated flame retardants in the environment. Chemosphere 2002, 46:583-624.
29. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990, 13:281-285.
30. Dick F.D., De Palma G., Ahmadi A., Scott N.W., Prescott G.J., Bennett J., et al. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup Environ Med 2007, 64:666-672.
31. Dobson A.W., Erikson K.M., Aschner M. Manganese neurotoxicity. Ann N Y Acad Sci 2004, 1012:115-128.
32. Dreiem A., Shan M., Okoniewski R.J., Sanchez-Morrissey S., Seegal R.F. Methylmercury inhibits dopaminergic function in rat pup synaptosomes in an age-dependent manner. Neurotoxicol Teratol 2009, 31:312-317.
33. Ehringer H., Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 1960, 38:1236-1239.
34. Erickson B.D. Analytical chemistry of PCBs 1986, Butterworth, Boston.
35. Eriksson H., Tedroff J., Thuomas K.A., Aquilonius S.M., Hartvig P., Fasth K.J., et al. Manganese induced brain lesions in Macaca fascicularis as revealed by positron emission tomography and magnetic resonance imaging. Arch Toxicol 1992, 66:403-407.
36. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003, 991:1-14.
37. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351:2498-2508.
38. Faroon O., Jones D., de Rosa C. Effects of polychlorinated biphenyls on the nervous system. Toxicol Ind Health 2001, 16:305-333.
39. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006, 7:306-318.
40. Fechter L.D., Johnson D.L., Lynch R.A. The relationship of particle size to olfactory nerve uptake of a non-soluble form of manganese into brain. Neurotoxicology 2002, 23:177-183.
41. Feldman R.G., Mayer R., Taub A. Evidence for peripheral neurotoxic effect of trichloroethylene. Neurology 1970, 20:599-606.
42. Feldman R.G., White R.F., Currie J.N., Travers P.H., Lessell S. Long-term follow-up after single toxic exposure to trichloroethylene. Am J Ind Med 1985, 8:119-126.
43. 2+ ion concentrations in cultured rat hippocampal neurons by a calmodulin-dependent mechanism. Neurotoxicology 2000, 21:365-378.
44. Finkelstein Y., Vardi J. Progressive parkinsonism in a young experimental physicist following long-term exposure to methanol. Neurotoxicology 2002, 23:521-525.
45. Fonnum F., Mariussen E., Reistad T. Molecular mechanisms involved in the toxic effects of polychlorinated biphenyls (PCBs) and brominated flame retardants (BFRs). J Toxicol Environ Health A 2006, 69:21-35.
46. Forno L.S. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996, 55:259-272.
47. Friedman A., Arosio P., Finazzi D., Koziorowski D., Galazka-Friedman J. Ferritin as an important player in neurodegeneration. Parkinsonism Relat Disord 2011, 17:423-430.
48. Gao H.M., Hong J.S. Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Prog Neurobiol 2011, 94:1-19.
49. Gash D.M., Rutland K., Hudson N.L., Sullivan P.G., Bing G., Cass W.A., et al. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol 2008, 63:184-192.
50. Gavin C.E., Gunter K.K., Gunter T.E. Manganese and calcium transport in mitochondria: implications for manganese toxicity. Neurotoxicology 1999, 20:445-453.
51. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
52. Gibbs J.P., Crump K.S., Houck D.P., Warren P.A., Mosley W.S. Focused medical surveillance: a search for subclinical movement disorders in a cohort of U.S. workers exposed to low levels of manganese dust. Neurotoxicology 1999, 20:299-313.
53. Gmerek D.E., McCafferty M.R., O'Neill K.J., Melamed B.R., O'Neill J.J. Effect of inorganic lead on rat brain mitochondrial respiration and energy production. J Neurochem 1981, 36:1109-1113.
54. Goldman S.M. Trichloroethylene and Parkinson's disease: dissolving the puzzle. Expert Rev Neurother 2010, 10:835-837.
55. Goldman S.M., Quinlan P.J., Ross G.W., Marras C., Meng C., Bhudhikanok G.S., et al. Solvent exposures and parkinson disease risk in twins. Ann Neurol 2011.
56. Golub M.S., Hogrefe C.E., Germann S.L., Tran T.T., Beard J.L., Crinella F.M., et al. Neurobehavioral evaluation of rhesus monkey infants fed cow's milk formula, soy formula, or soy formula with added manganese. Neurotoxicol Teratol 2005, 27:615-627.
57. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Brown G.G., et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997, 48:650-658.
58. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Brown G.G., et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 1999, 20:239-247.
59. Gorell J.M., Rybicki B.A., Cole Johnson C., Peterson E.L. Occupational metal exposures and the risk of Parkinson's disease. Neuroepidemiology 1999, 18:303-308.
60. Gotz M.E., Koutsilieri E., Riederer P., Ceccatelli S., Dare E. Methylmercury induces neurite degeneration in primary culture of mouse dopaminergic mesencephalic cells. J Neural Transm 2002, 109:597-605.
61. Goyer R.A. Results of lead research: prenatal exposure and neurological consequences. Environ Health Perspect 1996, 104:1050-1054.
62. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978, 14:633-643.
63. Graham D.G., Tiffany S.M., Bell W.R., Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978, 14:644-653.
64. Guehl D., Bezard E., Dovero S., Boraud T., Bioulac B., Gross C. Trichloroethylene and parkinsonism: a human and experimental observation. Eur J Neurol 1999, 6:609-611.
65. Guilarte T.R. Manganese and Parkinson's disease: a critical review and new findings. Environ Health Perspect 2010, 118:1071-1080.
66. Guilarte T.R., Chen M.K., McGlothan J.L., Verina T., Wong D.F., Zhou Y., et al. Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Exp Neurol 2006, 202:381-390.
67. Halliwell B., Gutteridge J.M. Role of iron in oxygen radical reactions. Methods Enzymol 1984, 105:47-56.
68. Hare M.F., Rezazadeh S.M., Cooper G.P., Minnema D.J., Michaelson I.A. Effects of inorganic mercury on [3H]dopamine release and calcium homeostasis in rat striatal synaptosomes. Toxicol Appl Pharmacol 1990, 102:316-330.
69. Harris E.D. Cellular copper transport and metabolism. Annu Rev Nutr 2000, 20:291-310.
70. Hatcher J.M., Pennell K.D., Miller G.W. Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol Sci 2008, 29:322-329.
71. Hellman N.E., Gitlin J.D. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002, 22:439-458.
72. Hitoshi S., Iwata M., Yoshikawa K. Mid-brain pathology of Wilson's disease: MRI analysis of three cases. J Neurol Neurosurg Psychiatry 1991, 54:624-626.
73. 2 nanoparticles. Biomaterials 2010, 31:8043-8050.
74. Huang C.C., Chu N.S., Lu C.S., Wang J.D., Tsai J.L., Tzeng J.L., et al. Chronic manganese intoxication. Arch Neurol 1989, 46:1104-1106.
75. Huang C.C., Lu C.S., Chu N.S., Hochberg F., Lilienfeld D., Olanow W., et al. Progression after chronic manganese exposure. Neurology 1993, 43:1479-1483.
76. Huang R., Han L., Li J., Ren F., Ke W., Jiang C., et al. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. J Gene Med 2009, 11:754-763.
77. Huber F. Clinical aspects and neuropathology of trichloroethylene poisoning. Z Unfallmed Berufskr 1969, 62:226-267.
78. Hudnell H.K. Effects from environmental Mn exposures: a review of the evidence from non-occupational exposure studies. Neurotoxicology 1999, 20:379-397.
79. Hurley L.S., Keen C.L., Baly D.L. Manganese deficiency and toxicity: effects on carbohydrate metabolism in the rat. Neurotoxicology 1984, 5:97-104.
80. Hussain S.M., Javorina A.K., Schrand A.M., Duhart H.M., Ali S.F., Schlager J.J. The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion. Toxicol Sci 2006, 92:456-463.
81. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003, 53(Suppl. 3):S26-S36. discussion S36-28.
82. Junxia X., Hong J., Wenfang C., Ming Q. Dopamine release rather than content in the caudate putamen is associated with behavioral changes in the iron rat model of Parkinson's disease. Exp Neurol 2003, 182:483-489.
83. Kamrin M.A., Fischer L.J., Suk W.A., Fouts J.R., Pellizzari E., Thornton K. Assessment of human exposure to chemicals from Superfund sites. Environ Health Perspect 1994, 102(Suppl. 1):221-228.
84. Kaur D., Peng J., Chinta S.J., Rajagopalan S., Di Monte D.A., Cherny R.A., et al. Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging 2007, 28:907-913.
85. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003, 37:899-909.
86. Kim Y., Kim J.M., Kim J.W., Yoo C.I., Lee C.R., Lee J.H., et al. Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean?. Mov Disord 2002, 17:568-575.
87. Kochen W., Kohlmuller D., De Biasi P., Ramsay R. The endogeneous formation of highly chlorinated tetrahydro-beta-carbolines as a possible causative mechanism in idiopathic Parkinson's disease. Adv Exp Med Biol 2003, 527:253-263.
88. Kodavanti P.R., Derr-Yellin E.C. Differential effects of polybrominated diphenyl ethers and polychlorinated biphenyls on [3H]arachidonic acid release in rat cerebellar granule neurons. Toxicol Sci 2002, 68:451-457.
89. 2+ buffering and protein kinase C activity in the absence of changes in tyrosine hydroxylase. Toxicol Appl Pharmacol 1998, 153:186-198.
90. Kodavanti P.R., Ward T.R. Differential effects of commercial polybrominated diphenyl ether and polychlorinated biphenyl mixtures on intracellular signaling in rat brain in vitro. Toxicol Sci 2005, 85:952-962.
91. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
92. Lasley S.M., Gilbert M.E. Presynaptic glutamatergic function in dentate gyrus in vivo is diminished by chronic exposure to inorganic lead. Brain Res 1996, 736:125-134.
93. Lee D.W., Notter S.A., Thiruchelvam M., Dever D.P., Fitzpatrick R., Kostyniak P.J., et al. Subchronic polychorinated biphenyl (Aroclor 1254) exposure produces oxidative damage and neuronal death of ventral midbrain dopaminergic systems. Toxicol Sci 2011.
94. Lee D.W., Opanashuk L.A. Polychlorinated biphenyl mixture aroclor 1254-induced oxidative stress plays a role in dopaminergic cell injury. Neurotoxicology 2004, 25:925-939.
95. Ley C.O., Gali F.G. Parkinsonian syndrome after methanol intoxication. Eur Neurol 1983, 22:405-409.
96. Lin C.Y., Liou S.H., Hsiech C.M., Ku M.C., Tsai S.Y. Dose-response relationship between cumulative mercury exposure index and specific uptake ratio in the striatum on Tc-99m TRODAT SPECT. Clin Nucl Med 2011, 36:689-693.
97. Liu M., Choi D.-Y., Hunter R.L., Pandya J.D., Cass W.A., Sullivan P.G., et al. Trichloroethylene induces dopaminergic neurodegeneration in Fisher 344 rats. J Neurochem 2010, 112:773-783.
98. Luross J.M., Alaee M., Sergeant D.B., Cannon C.M., Whittle D.M., Solomon K.R., et al. Spatial distribution of polybrominated diphenyl ethers and polybrominated biphenyls in lake trout from the Laurentian Great Lakes. Chemosphere 2002, 46:665-672.
99. Lyng G.D., Seegal R.F. Polychlorinated biphenyl-induced oxidative stress in organotypic co-cultures: experimental dopamine depletion prevents reductions in GABA. Neurotoxicology 2008, 29:301-308.
100. Lyng G.D., Snyder-Keller A., Seegal R.F. Polychlorinated biphenyl-induced neurotoxicity in organotypic cocultures of developing rat ventral mesencephalon and striatum. Toxicol Sci 2007, 97:128-139.
101. Madia F., Giordano G., Fattori V., Vitalone A., Branchi I., Capone F., et al. Differential in vitro neurotoxicity of the flame retardant PBDE-99 and of the PCB Aroclor 1254 in human astrocytoma cells. Toxicol Lett 2004, 154:11-21.
102. Manton W.I., Angle C.R., Krogstrand K.L. Origin of lead in the United States diet. Environ Sci Technol 2005, 39:8995-9000.
103. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984, 311:464-467.
104. Marsh G.M., Gula M.J. Employment as a welder and Parkinson disease among heavy equipment manufacturing workers. J Occup Environ Med 2006, 48:1031-1046.
105. Maynard L.S., Cotzias G.C. The partition of manganese among organs and intracellular organelles of the rat. J Biol Chem 1955, 214:489-495.
106. McLean D.R., Jacobs H., Mielke B.W. Methanol poisoning: a clinical and pathological study. Ann Neurol 1980, 8:161-167.
107. Modi G., Pillay V., Choonara Y.E., Ndesendo V.M., du Toit L.C., Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol 2009, 88:272-285.
108. Normandin L., Ann Beaupre L., Salehi F., St-Pierre A., Kennedy G., Mergler D., et al. Manganese distribution in the brain and neurobehavioral changes following inhalation exposure of rats to three chemical forms of manganese. Neurotoxicology 2004, 25:433-441.
109. Norstrom R.J., Simon M., Moisey J., Wakeford B., Weseloh D.V. Geographical distribution (2000) and temporal trends (1981-2000) of brominated diphenyl ethers in Great Lakes hewing gull eggs. Environ Sci Technol 2002, 36:4783-4789.
110. Oberdorster G., Oberdorster E., Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005, 113:823-839.
111. Oberdorster G., Elder A., Rinderknecht A. Nanoparticles and the brain: cause for concern?. J Nanosci Nanotecnol 2009, 9:4996-5007.
112. Oder W., Prayer L., Grimm G., Spatt J., Ferenci P., Kollegger H., et al. Wilson's disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology 1993, 43:120-124.
113. Olanow C.W. Manganese-induced parkinsonism and Parkinson's disease. Ann N Y Acad Sci 2004, 1012:209-223.
114. Olanow C.W., Good P.F., Shinotoh H., Hewitt K.A., Vingerhoets F., Snow B.J., et al. Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology 1996, 46:492-498.
115. Pal P.K., Samii A., Calne D.B. Manganese neurotoxicity: a review of clinical features, imaging and pathology. Neurotoxicology 1999, 20:227-238.
116. Paris I., Perez-Pastene C., Couve E., Caviedes P., Ledoux S., Segura-Aguilar J. Copper dopamine complex induces mitochondrial autophagy preceding caspase-independent apoptotic cell death. J Biol Chem 2009, 284:13306-13315.
117. Priyadarshi A., Khuder S.A., Schaub E.A., Shrivastava S. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 2000, 21:435-440.
118. Reddy N.J., Lewis L.D., Gardner T.B., Osterling W., Eskey C.J., Nierenberg D.W. Two cases of rapid onset Parkinson's syndrome following toxic ingestion of ethylene glycol and methanol. Clin Pharmacol Ther 2007, 81:114-121.
119. Reddy N.J., Sudini M., Lewis L.D. Delayed neurological sequelae from ethylene glycol, diethylene glycol and methanol poisonings. Clin Toxicol (Phila) 2010, 48:967-973.
120. Reistad T., Fonnum F., Mariussen E. Neurotoxicity of the pentabrominated diphenyl ether mixture, DE-71, and hexabromocyclododecane (HBCD) in rat cerebellar granule cells in vitro. Arch Toxicol 2006, 80:785-796.
121. Reistad T., Mariussen E., Fonnum F. The effect of a brominated flame retardant, tetrabromobisphenol-A, on free radical formation in human neutrophil granulocytes: the involvement of the MAP kinase pathway and protein kinase C. Toxicol Sci 2005, 83:89-100.
122. Reistad T., Mariussen E., Ring A., Fonnum F. In vitro toxicity of tetrabromobisphenol-A on cerebellar granule cells: cell death, free radical formation, calcium influx and extracellular glutamate. Toxicol Sci 2007, 96:268-278.
123. Richardson J.R., Miller G.W. Acute exposure to aroclor 1016 or 1260 differentially affects dopamine transporter and vesicular monoamine transporter 2 levels. Toxicol Lett 2004, 148:29-40.
124. Rossi L., Lombardo M.F., Ciriolo M.R., Rotilio G. Mitochondrial dysfunction in neurodegenerative diseases associated with copper imbalance. Neurochem Res 2004, 29:493-504.
125. Safe S. Toxicology, structure-function relationship, and human and environmental health impacts of polychlorinated biphenyls: progress and problems. Environ Health Perspect 1993, 100:259-268.
126. Santamaria A.B., Cushing C.A., Antonini J.M., Finley B.L., Mowat F.S. State-of-the-science review: does manganese exposure during welding pose a neurological risk?. J Toxicol Environ Health 2007, 10:417-465.
127. Schapira A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008, 7:97-109.
128. Schroeder H.A., Balassa J.J., Tipton I.H. Essential trace metals in man: manganese. A study in homeostasis. J Chronic Dis 1966, 19:545-571.
129. Scortegagna M., Hanbauer I. The effect of lead exposure and serum deprivation on mesencephalic primary cultures. Neurotoxicology 1997, 18:331-339.
130. Seegal R.F., Brosch K., Bush B., Ritz M., Shain W. Effects of Aroclor 1254 on dopamine and norepinephrine concentrations in pheochromocytoma (PC-12) cells. Neurotoxicology 1989, 10:757-764.
131. Seegal R.F., Brosch K.O., Bush B. Polychlorinated biphenyls produce regional alterations of dopamine metabolism in rat brain. Toxicol Lett 1986, 30:197-202.
132. Seegal R.F., Bush B., Brosch K.O. Sub-chronic exposure of the adult rat to Aroclor 1254 yields regionally-specific changes in central dopaminergic function. Neurotoxicology 1991, 12:55-65.
133. Seegal R.F., Bush B., Brosch K.O. Decreases in dopamine concentrations in adult, non-human primate brain persist following removal from polychlorinated biphenyls. Toxicology 1994, 86:71-87.
134. Seegal R.F., Bush B., Shain W. Lightly chlorinated ortho-substituted PCB congeners decrease dopamine in nonhuman primate brain and in tissue culture. Toxicol Appl Pharmacol 1990, 106:136-144.
135. Seegal R.F., Marek K.L., Seibyl J.P., Jennings D.L., Molho E.S., Higgins D.S., et al. Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: a beta-CIT imaging study. Neurobiol Dis 2010, 38:219-225.
136. Seegal R.F., Pappas B.A., Park G.A. Neurochemical effects of consumption of Great Lakes salmon by rats. Regul Toxicol Pharmacol 1998, 27:S68-S75.
137. Seidler A., Hellenbrand W., Robra B.P., Vieregge P., Nischan P., Joerg J., et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996, 46:1275-1284.
138. Semchuk K.M., Love E.J., Lee R.G. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993, 43:1173-1180.
139. Sengstock G.J., Olanow C.W., Dunn A.J., Barone S., Arendash G.W. Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra. Exp Neurol 1994, 130:82-94.
140. Shain W., Bush B., Seegal R. Neurotoxicity of polychlorinated biphenyls: structure-activity relationship of individual congeners. Toxicol Appl Pharmacol 1991, 111:33-42.
141. Shinotoh H., Snow B.J., Hewitt K.A., Pate B.D., Doudet D., Nugent R., et al. MRI and PET studies of manganese-intoxicated monkeys. Neurology 1995, 45:1199-1204.
142. Sjodin A., Jones R.S., Focant J.F., Lapeza C., Wang R.Y., McGahee E.E., et al. Retrospective time-trend study of polybrominated diphenyl ether and polybrominated and polychlorinated biphenyl levels in human serum from the United States. Environ Health Perspect 2004, 112:654-658.
143. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988, 74:199-205.
144. Steenland K., Hein M.J., Cassinelli R.T., Prince M.M., Nilsen N.B., Whelan E.A., et al. Polychlorinated biphenyls and neurodegenerative disease mortality in an occupational cohort. Epidemiology 2006, 17:8-13.
145. Suzuki Y., Mouri T., Suzuki Y., Nishiyama K., Fujii N. Study of subacute toxicity of manganese dioxide in monkeys. Tokushima J Exp Med 1975, 22:5-10.
146. Tanner C.M., Ottman R., Goldman S.M., Ellenberg J., Chan P., Mayeux R., et al. Parkinson disease in twins: an etiologic study. JAMA 1999, 281:341-346.
147. Tavakoli-Nezhad M., Barron A.J., Pitts D.K. Postnatal inorganic lead exposure decreases the number of spontaneously active midbrain dopamine neurons in the rat. Neurotoxicology 2001, 22:259-269.
148. Taylor T.N., Caudle W.M., Shepherd K.R., Noorian A., Jackson C.R., Iuvone P.M., et al. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci 2009, 29:8103-8113.
149. Teng S., Beard K., Pourahmad J., Moridani M., Easson E., Poon R., et al. The formaldehyde metabolic detoxification enzyme systems and molecular cytotoxic mechanism in isolated rat hepatocytes. Chem Biol Interact 2001, 130-132:285-296.
150. Tjalve H., Henriksson J. Uptake of metals in the brain via olfactory pathways. Neurotoxicology 1999, 20:181-195.
151. Tuite P.J., Krawczewski K. Parkinsonism: a review-of-systems approach to diagnosis. Semin Neurol 2007, 27:113-122.
152. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 2001, 276:44284-44296.
153. Verslegers W., Van den Kerchove M., Crols R., De Potter W., Appel B., Lowenthal A. Methanol intoxication. Parkinsonism and decreased Met-enkephalin levels due to putaminal necrosis. Acta Neurol Belg 1988, 88:163-171.
154. Villaume J., Wasti K., Liss-Sutter D., Hsaio S. Effects of welding on health 1979, Welding Society, Miami, FL, p. 1-121.
155. Vitarella D., Wong B.A., Moss O.R., Dorman D.C. Pharmacokinetics of inhaled manganese phosphate in male Sprague-Dawley rats following subacute (14-day) exposure. Toxicol Appl Pharmacol 2000, 163:279-285.
156. Wang J., Rahman M.F., Duhart H.M., Newport G.D., Patterson T.A., Murdock R.C., et al. Expression changes of dopaminergic system-related genes in PC12 cells induced by manganese, silver, or copper nanoparticles. Neurotoxicology 2009, 30:926-933.
157. Weisskopf M.G., Weuve J., Nie H., Saint-Hilaire M.H., Sudarsky L., Simon D.K., et al. Association of cumulative lead exposure with Parkinson's disease. Environ Health Perspect 2010, 118:1609-1613.
158. Win-Shwe T.T., Fujimaki H. Nanoparticles and neurotoxicity. Int J Mol Sci 2011, 12:6267-6280.
159. Wirdefeldt K., Adami H.O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011, 26(Suppl. 1):S1-S58.
160. Wright A.K., Atherton J.F., Norrie L., Arbuthnott G.W. Death of dopaminergic neurones in the rat substantia nigra can be induced by damage to globus pallidus. Eur J Neurosci 2004, 20:1737-1744.
161. Wu J., Wang C., Sun J., Xue Y. Neurotoxicity of silica nanoparticles: brain localization and dopaminergic neurons damage pathways. ACS Nano 2011, 5:4476-4489.
162. Yee S., Choi B.H. Oxidative stress in neurotoxic effects of methylmercury poisoning. Neurotoxicology 1996, 17:17-26.
163. Yin Z., Jiang H., Syversen T., Rocha J.B., Farina M., Aschner M. The methylmercury-l-cysteine conjugate is a substrate for the L-type large neutral amino acid transporter. J Neurochem 2008, 107:1083-1090.
164. Yoshida M., Fukabori S., Hara K., Yuasa H., Nakaaki K., Yamamura Y., et al. Concentrations of trichloroethylene and its metabolites in blood and urine after acute poisoning by ingestion. Hum Exp Toxicol 1996, 15:254-258.
165. 2+) induces degeneration of dopaminergic neurons in the nigrostriatal system of rats. Neurosci Bull 2008, 24:73-78.